NHC

公司名称：National HealthCare Corporation

主要经营地：🇺🇸 美国

详细生意模式：【做空】30年内部人租约与NHI年底到期，租金从低于市价~43%重置为公允价值=$25-35M加租（~20% EBITDA打击）。50%床位/收入面临NHI更换运营商风险。CMS数据：22/80设施<2星，49%护士流失率。必须增加$23M人工成本以满足CMS新人员配置要求。

护城河：🔴弱

估值水平：PT暗示~58%下行，仅3% SI

EV/Market Cap：3%做空利息=市场未充分认识风险

网络观点：🔴 Bearish：租约重置+人员成本+质量问题三重风险

AI观点：✅ NHC做空论点极为扎实：(1) 30年低于市价43%的租约到期重置是确定性利空；(2) CMS质量数据堪忧（22/80设施<2星）；(3) 新人员配置要求增加$23M成本；(4) Medicare Advantage侵蚀高利润率传统Medicare。3%做空利息意味着市场尚未充分定价这些风险。催化剂时间线清晰（2026各季度）。

原文日期：2026-01-27

National HealthCare Corporation (NHC) is a healthcare services provider with a market cap of $2.46 billion. The company's stock is considered to be trading at a significant discount to its fair value. It is also a reliable dividend payer with a current yield of 1.62%. However, there has been significant insider selling in the past three months, and profit margins have declined compared to the previous year. The company has a good balance sheet with a low debt-to-equity ratio. The stock has outperformed the US Healthcare industry and the broader US market over the past year.

The National HealthCare Corp stock holds a sell signal from the short-term Moving Average, but a buy signal from the long-term average. There is a general buy signal in the stock giving a positive forecast. The stock is considered to be high risk with high volatility. Insider sentiment is negative, with significant open-market selling from key executives. The overall evaluation results in a strongly negative Insider Power Score. The system gives more weight to recent, high-impact sales from key executives than to routine, low-impact transactions like stock awards or option exercises.

National HealthCare Corporation (NHC) is a healthcare company with a market cap of $2.63 billion, operating in the Medical Care Facilities industry. The company provides a wide range of services, including skilled nursing, assisted and independent living, homecare, and hospice. The stock has shown significant appreciation, reaching the high point of its 52-week range. Despite strong revenue growth of 12.50%, key valuation metrics like the P/E ratio are unavailable, making valuation challenging. However, the company has a solid EPS of $6.48 and a commendable ROE of 10.12%. With over $120 million in free cash flow, NHC has the flexibility for reinvestment and dividends. The stock has a modest dividend yield of 1.51%. While there are no analyst ratings, the RSI suggests the stock might be oversold, presenting a potential buying opportunity. NHC's diverse service portfolio and long history position it well for future growth in the evolving healthcare sector.